Clinical Trial Info

Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT

Authored by

A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD therapies.

Duration of study: 60 weeks